GLTO
vs
S&P 500
GLTO
S&P 500
Over the past 12 months, GLTO has significantly outperformed S&P 500, delivering a return of +628% compared to S&P 500's +18% growth.
Stocks Performance
GLTO vs S&P 500
Performance Gap
GLTO vs S&P 500
Performance By Year
GLTO vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Galecto Inc
Glance View
Galecto Inc. is a biotechnology company that tries to develop new medicines for serious diseases driven by scarring, inflammation, and cancer. Its work centers on drug candidates that block biological targets such as galectin-3 and LOXL2, which are involved in fibrosis and tumor growth. In simple terms, Galecto is not a drug seller today; it is a research company looking for compounds that can become approved treatments later. The people who would use its medicines are patients treated by doctors in hospitals and specialist clinics, especially in areas like lung disease, liver disease, and cancer care. Because Galecto is still in development mode, it does not make money like a normal commercial pharmaceutical company. Its business depends on raising capital, and any future revenue would likely come from selling approved drugs, licensing its drug rights, or forming partnership deals with larger drug companies. What makes Galecto different is its narrow focus on a few biological targets rather than a broad portfolio of marketed drugs. That puts it in the high-risk, high-reward part of biotech, where most of the value comes from whether a small set of experimental therapies can clear clinical and regulatory hurdles. If those programs work, the company could become a specialist supplier of treatments for diseases with limited options.
